26 Recruiting Non Small Cell Lung Cancer Phase 1 Clinical Trials
Active phase 1 studies for non small cell lung cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Non Small Cell Lung Cancer studiesPhase 1 Studies for Non Small Cell Lung Cancer
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
📍 Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
View Study & Checklist ➔A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
📍 Highlands Oncology Group - Duplicate 2 — Springdale, Arkansas
View Study & Checklist ➔A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
📍 City of Hope — Duarte, California
View Study & Checklist ➔Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View Study & Checklist ➔Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial
📍 BC Cancer -Vancouver Island — Vancouver, British Columbia
View Study & Checklist ➔Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
📍 UCLA Hematology/Oncology — Santa Monica, California
View Study & Checklist ➔Study of NEO-201 in Solid Tumors Expansion Cohorts
📍 National Cancer Institute — Bethesda, Maryland
View Study & Checklist ➔A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
📍 BRCR Global — Plantation, Florida
View Study & Checklist ➔UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
📍 UC Davis Medical Center — Sacramento, California
View Study & Checklist ➔A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
📍 Pacific Cancer Medical Center, Inc — Anaheim, California
View Study & Checklist ➔Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
📍 Rocky Mountain Cancer Center, LLP — Boulder, Colorado
View Study & Checklist ➔Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
📍 Site 9618 — Tucson, Arizona
View Study & Checklist ➔3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial
📍 St. Joseph's Healthcare Hamilton — Hamilton, Ontario
View Study & Checklist ➔Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
📍 Mayo Clinic Scottsdale — Scottsdale, Arizona
View Study & Checklist ➔A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
📍 Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
View Study & Checklist ➔Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
📍 Cedars-Sinai Cancer at Beverly Hills (THO) — Beverly Hills, California
View Study & Checklist ➔Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
📍 D&H Cancer Research Center — Margate, Florida
View Study & Checklist ➔This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
📍 Centre Hospitalier de l'Université de Montréal — Montreal, Quebec
View Study & Checklist ➔EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
📍 VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
View Study & Checklist ➔Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
📍 Carolina BioOncology Institute — Huntersville, North Carolina
View Study & Checklist ➔A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
📍 Community Health Network — Indianapolis, Indiana
View Study & Checklist ➔First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
📍 Karmanos Cancer Institute — Detroit, Michigan
View Study & Checklist ➔